GSA Capital Partners LLP Sells 83,999 Shares of Immunic, Inc. (NASDAQ:IMUX)

GSA Capital Partners LLP decreased its stake in shares of Immunic, Inc. (NASDAQ:IMUX) by 71.9% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 32,766 shares of the company’s stock after selling 83,999 shares during the period. GSA Capital Partners LLP’s holdings in Immunic were worth $54,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in IMUX. Vanguard Group Inc. lifted its holdings in shares of Immunic by 100.7% in the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after buying an additional 1,703,047 shares in the last quarter. Janus Henderson Group PLC bought a new stake in Immunic during the 1st quarter worth approximately $9,266,000. Ikarian Capital LLC lifted its stake in Immunic by 258.3% in the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock worth $2,128,000 after purchasing an additional 1,162,378 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Immunic in the 1st quarter valued at $25,000. Institutional investors own 51.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. B. Riley began coverage on Immunic in a research note on Tuesday, August 27th. They set a “buy” rating and a $6.00 price objective for the company. EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a research report on Monday, September 16th. Leerink Partners reissued an “outperform” rating and issued a $5.00 price target on shares of Immunic in a report on Monday, September 9th. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Finally, HC Wainwright began coverage on Immunic in a research note on Monday. They set a “buy” rating and a $10.00 price target for the company. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $11.80.

Insider Buying and Selling at Immunic

In other news, Director Richard Alan Rudick purchased 87,300 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was bought at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the acquisition, the director now directly owns 87,300 shares of the company’s stock, valued at $100,395. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 3.00% of the company’s stock.

Immunic Trading Up 7.3 %

NASDAQ IMUX opened at $1.18 on Tuesday. The firm has a market cap of $106.29 million, a PE ratio of -0.96 and a beta of 1.88. Immunic, Inc. has a 1-year low of $0.97 and a 1-year high of $2.11. The stock has a 50-day moving average of $1.39 and a 200-day moving average of $1.34.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.